» Articles » PMID: 25339434

Current Concept and Epidemiology of Systemic Vasculitides

Overview
Journal Allergol Int
Publisher Elsevier
Date 2014 Oct 24
PMID 25339434
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Although a new classification algorithm for systemic vasculitides was proposed by Watts et al. and the Chapel Hill Consensus Conference (CHCC) was updated in 2012, there are currently no validated diagnostic criteria for systemic vasculitides. The Diagnostic and Classification Criteria for Vasculitis study (DCVAS) is a global study to develop and improve the diagnostic criteria for systemic vasculitides. The epidemiology of systemic vasculitides differs widely among countries. For example, in the case of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, patients with microscopic polyangiitis (MPA) and with positivity for MPO-ANCA are predominant in Asian countries, whereas patients with granulomatosis with polyangiitis (GPA) and with positivity for PR3-ANCA are predominant in northern Europe and the United States. Interstitial lung disease (ILD) occurs more frequently in Asian patients compared with patients in Europe. The incidence and the prevalence of large-vessel vasculitis also differ significantly. Giant cell arteritis (GCA) occurs frequently in northern Europe, unlike Takayasu arteritis (TAK). The ethnic and regional differences in the incidence, prevalence and clinical characteristics of patients with vasculitis should be recognized when we diagnose and treat patients with vasculitis using criteria, and should also be considered when interpreting the results from clinical studies.

Citing Articles

Vasculitis and infectious risk in a patient with type 2 diabetes mellitus: A case report.

Mitroi R, Rosu M, Clenciu D, Padureanu V, Mitrea A, Grigore M Exp Ther Med. 2024; 27(5):234.

PMID: 38628659 PMC: 11019656. DOI: 10.3892/etm.2024.12522.


The pharmacological treatment of granulomatosis with polyangiitis: a review of clinical trials registered in clinicaltrials.gov and the International Clinical Trials Registry Platform.

Sultana J, Camilleri N, Crisafulli S, Borg J, Spagnol S, Tillati S Ther Adv Rare Dis. 2023; 4:26330040231213888.

PMID: 38116207 PMC: 10729619. DOI: 10.1177/26330040231213888.


Identification of new risk loci shared across systemic vasculitides points towards potential target genes for drug repurposing.

Ortiz-Fernandez L, Carmona E, Kerick M, Lyons P, Carmona F, Lopez Mejias R Ann Rheum Dis. 2023; 82(6):837-847.

PMID: 36797040 PMC: 10314028. DOI: 10.1136/ard-2022-223697.


Anti-Inflammatory and/or Anti-Fibrotic Treatment of MPO-ANCA-Positive Interstitial Lung Disease: A Short Review.

Yamakawa H, Toyoda Y, Baba T, Kishaba T, Fukuda T, Takemura T J Clin Med. 2022; 11(13).

PMID: 35807120 PMC: 9267459. DOI: 10.3390/jcm11133835.


Utility of anti-neutrophil cytoplasmic antibody screening in idiopathic interstitial lung disease.

Fidler L, Kandel S, Fisher J, Mittoo S, Shapera S Sarcoidosis Vasc Diffuse Lung Dis. 2021; 38(2):e2021015.

PMID: 34316255 PMC: 8288199. DOI: 10.36141/svdld.v38i2.10971.